- "Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston - VANCOUVER, Jan. 23, 2019 /CNW/ - Sierra Oncology, Inc....
- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks - - Data from...
- SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC) – - Activates immune signaling STING pathway - - Data reported at the AACR Conference on Tumor Immunology and...
View all news releases
Targeted Therapeutics for Hematology & Oncology – Q1 2019
View All Presentations
Location: Boston, MA
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts